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Lymphomas are malignancies of the B or T lymphocytes. Due
to the heterogeneity of this disease,ﬁnding aneffective formof
treatment is challenging. One treatment option is hemato-
logical stem cell transplantation (HSCT), whose success partly
depends on the efﬁcacy of the pretransplant regimen. Nucle-
oside analogs such as gemcitabine (Gem) and clofarabine (Clo)
are being used as part of pretransplant conditioning therapy
for lymphoma patients. To improve the cytotoxicity of these
drugs, we studied their synergism with edelfosine (Ed), an
alkyl phospholipid with different mechanisms of antitumor
activity, using cell linemodels. Exposure of the J45.01 and SUP-
T1 (T-cell) and theOCI-LY10 (B-cell) lymphoma cell lines to IC10
e IC20 levels of the drugs resulted in strong synergistic cyto-
toxicity. While the individual drugs inhibited J45.01 cell pro-
liferation by 3-19%, their combination inhibited proliferation
by w85%. 8-13% of J45.01 cells exposed to individual drugs
underwent apoptosis, which increased to 71% for the triple-
drug combination. Cell death correlated with increased
phosphorylation of histone 2AX and KAP1, decreased mito-
chondrial transmembrane potential, increased production of
reactive oxygen species, and release of pro-apoptotic factors.
Apoptosis was indicated by cleavage of PARP-1, caspases 3 and
8,MCL1 and ANP32B. Exposure of caspase 8-negative I9.2 cells
to [Gem+Clo+Ed] resulted in 40% inhibition of proliferation (as
compared with 85% inhibition in caspase 8-positive J45.01
cells), suggesting the relevance of caspases in the antitumor
activity of the three-drug combination. These observations are
consistent with a decreased level of phosphorylation of the
prosurvival protein AKT in cells exposed to [Gem+Clo+Ed]. The
three-drug combination also activated the SAPK/JNK stress
signaling pathway, which resulted in the phosphorylation and
heterodimerization of the transcription factors ATF2 and c-Jun,
two proteins involved in the DNA-damage response and
apoptosis.
It is possible that [Gem+Clo+Ed] is stem cell sparing and
should be investigated as salvage therapy in its own right;
however, to further improve antitumor efﬁcacy, we investi-
gated the possible further synergism of the three drugs when
combined with a DNA alkylating agent. Exposure of J45.01 to
lower concentrations of the drugs (15 nMGem, 25 nM Clo, 1.2
mg/ml Ed) in the presence of 6 mg/ml busulfan (Bu) or 0.18 mg/
ml melphalan (Mel) resulted in stronger synergistic cytotox-
icity.While the lower concentrations of [Gem+Clo+Ed] caused
a moderate DNA damage response and apoptosis, addition of
either Bu or Mel greatly enhanced the drug-mediated effects.
Overall, these results can be used as amechanistic impetus for
evaluating [Gem+Clo+Ed]DNA alkylator as salvage therapy
for refractory NHL either in conventional dosing or as part of
preparative regimens for patients undergoing HSCT.235
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Introduction: Survival outcomes of chemotherapy resistant/
refractory, relapsed and other high-risk Non Hodgkin’s
Lymphoma (NHL) patients are poor despite available salvage
treatment strategies including immunotherapy, high dose
chemotherapy and autologous hematopoietic cell transplant
(HCT). Optimal subsequent therapies currently are not well
deﬁned. We explored the outcomes including efﬁcacy and
toxicities of the novel strategy with tandem autologous HCT
followed by non-myeloablative (NMA) allogeneic HCT using
total lymphoid irradiation and anti-thymocyte globulin
regimen in high-risk NHL patients.
Method: Between November 2007 and December 2012,
histologically proven NHL patients with high-risk features
were prospectively enrolled to the institutional based
tandem autologous HCT followed by NMA allogeneic HCT
protocol (tandem HCT). Pre-transplant characteristics and
transplant related parameters were recorded. We analyzed
and reported post-transplant outcomes including event free
survival (EFS), overall survival (OS), toxicities and adverse
events.
Results: A total of 34 high-risk NHL patients were enrolled
to the study between 2007 and 2012. Median age at
autologous HCT was 59 years (range, 30-69 years). Diagnosis
included 17 transformed diffuse large B cell lymphoma
(DLBCL), 7 high-risk T cell NHL, 6 relapsed/refractory DLBCL,
2 double-hit NHL, and 2 refractory follicular lymphoma.
Twelve patients were able to complete the pre-planned
tandem HCT. Median duration between autologous and
allogeneic HCT was 84.5 days (range, 66-211 days). Of 22
patients who did not undergo the pre-planned tandem HCT,
three had allogeneic HCT under other available institutional
based protocols. At the time of data analysis, with the me-
dian duration of follow up of 10 months, median EFS and OS
for the entire group were 6.4 months and 13.3 months
respectively. In 12 patients who underwent tandem HCT,
median EFS and OS were 37.7 months and not reached
respectively. The major causes of death were disease relapse
(14 patients, 41.2%) and transplant related complication (5
patients, 14.7%). Of 12 tandem HCT patients, two patients
(16.7%) died from disease relapse.
Conclusion: Survival outcomes of high-risk NHL are poor.
Tandem autologous/allogeneic HCT might be a feasible and
effective approach in these very high-risk patients. The most
common cause of treatment failure remained disease relapse
in these high-risk patients. Proper identiﬁcation and selec-
tion of high risk NHL who will beneﬁt from tandem autolo-
gous/allogeneic transplantation are challenging and warrant
further studies.
